Table 2.
Description of patients with severe fibrosis/cirrhosis at baseline regressing to F0–F1–F2 fibrosis by the end of follow-up.
| No regression |
Regression to F0–F1–F2 |
||
|---|---|---|---|
| (n = 40) | (n = 7) | Pc | |
| At baseline | |||
| Male gendera | 40 (100) | 7 (100) | Ntp |
| Age >40 yearsa | 34 (85.0) | 7 (100) | 0.6 |
| BMI (kg/m2)b | 21.5 (20.5–23.2) | 20.8 (19.4–22.0) | 0.3 |
| Zone of high HBV-endemicitya | 3 (7.5) | 0 | 0.9 |
| Alcohol consumption (glasses/day)a | 0.4 | ||
| 0 | 25 (65.8) | 3 (42.9) | |
| >0–2 | 7 (18.4) | 2 (28.6) | |
| >2 | 6 (15.8) | 2 (28.6) | |
| Cardiovascular diseasea | 10 (25.0) | 1 (14.3) | 0.5 |
| Diabetesa | 1 (2.5) | 0 | 0.9 |
| Fasting glycaemia (mmol/L)b | 5.1 (4.6–5.8) | 5.1 (4.2–5.4) | 0.4 |
| Fasting triglycerides (mmol/L)b | 1.87 (1.52–2.92) | 0.98 (0.59–1.62) | 0.007 |
| AIDS-defining illnessa | 19 (47.5) | 2 (28.6) | 0.4 |
| CD4+ cell count (/mm3)b | 400 (213–565) | 576 (540–759) | 0.009 |
| CD4+ cell count (≥350/mm3)a | 21 (53.9) | 7 (100) | 0.03 |
| Nadir CD4+ cell count (/mm3)b | 158 (78–304) | 305 (216–346) | 0.13 |
| Nadir CD4+ (≥250/mm3)a | 13 (35.1) | 4 (66.7) | 0.19 |
| HIV-RNA (<50 copies/mL)a | 26 (66.7) | 5 (71.4) | 0.9 |
| ART duration (years)b | 8.0 (6.2–10.6) | 7.5 (6.6–9.2) | 0.9 |
| PI-containing ARTa | 22 (55.0) | 2 (28.6) | 0.2 |
| HBV-DNA (log10 IU/mL)b | 3.32 (2.31–5.18) | 6.58 (1.78–7.38) | 0.7 |
| HBV-DNA <60 IU/mLa | 5 (12.5) | 2 (28.6) | 0.3 |
| HBeAg-positivea | 25 (62.5) | 5 (71.4) | 0.9 |
| ALT >2 × ULNa | 8 (21.1) | 3 (42.9) | 0.3 |
| Prothrombin timeb | 90 (82–96) | 96 (84–100) | 0.12 |
| Platelet count (109/L)b | 160 (114–201) | 195 (146–245) | 0.16 |
| <150 (109/L)a | 18 (45.0) | 2 (28.6) | 0.7 |
| Albumin (g/L)b | 44 (39–46) | 45 (40–47) | 0.5 |
| <36 g/La | 3 (7.7) | 0 | 0.9 |
| Hyaluronic acid (µg/mL)b | 58 (30–119) | 49 (33–81) | 0.7 |
| Previous LAM usea | 38 (95.0) | 7 (100) | 0.9 |
| Mutations at position rt204a,d | 19 (47.5) | 4 (57.1) | 0.6 |
| At end of follow-up | |||
| TDF duration (months)b | 72 (37–94) | 47 (23–94) | 0.3 |
| HBV-DNA (<60 IU/mL)a | 32 (80.0) | 6 (85.7) | 0.9 |
| HBeAg-seroclearancea,e | 10 (40.0) | 2 (40.0) | 0.9 |
| HBsAg-seroclearancea | 2 (5.0) | 0 | 0.9 |
| ALT >2 × ULNa | 3 (7.5) | 0 | 0.9 |
| AST >2 × ULNa | 2 (5.0) | 0 | 0.9 |
| Prothrombin timeb | 90 (83–98) | 97 (95–100) | 0.03 |
| Platelet count (109/L)b | 167 (115–213) | 201 (147–238) | 0.3 |
| <150 (109/L)a | 16 (40.0) | 2 (28.6) | 0.7 |
| Albumin (g/L)b | 43.1 (40.7–47.0) | 46.0 (40.8–49.0) | 0.4 |
| <36 g/La | 2 (5.1) | 0 | 0.9 |
| Hyaluronic acid (µg/mL)b | 43 (23–67) | 33 (10–57) | 0.4 |
| Fasting glycaemia (mmol/L)b | 5.1 (4.9–5.4) | 5.0 (4.9–5.1) | 0.5 |
| Fasting triglycerides (mmol/L)b | 1.64 (1.21–3.00) | 1.07 (0.85–2.05) | 0.09 |
| HIV-RNA (<50 copies/mL)a | 36 (90.0) | 7 (100) | 0.9 |
| Change in CD4+ cell countb | 18 (−63, 184) | 10 (−84, 39) | 0.7 |
| CD4+ cell count (≥500/mm3)a | 13 (33.3) | 6 (85.7) | 0.01 |
aNumber (%).
bMedian (IQR).
cSignificance between regression groups determined using Kruskal–Wallis test for continuous variables and Pearson’s χ 2 test or Fisher’s exact test for categorical variables. ntp: no test performed.
dPatients without documented resistance were considered not to have any rt204 mutations.
eOnly HBeAg-positive patients; four patients without regression seroreverted HBeAg-positive after seroclearance.